Malaria Prevention and Treatment Guidelines

Contraindications and Precautions

Doxiciclina is contraindicated in pregnant women and children under 8 years old due to potential tooth discoloration, dental dysplasia, and inhibition of bone growth in the fetus, and mefloquina is contraindicated in pregnant women and individuals with psychiatric disorders or epilepsy, as recommended by the Centers for Disease Control and Prevention (CDC) 1
Primaquine is contraindicated in patients with G6PD deficiency as it can cause severe hemolysis, and a laboratory test is required to rule out G6PD deficiency before using primaquine, according to the CDC 1
Halofantrina is contraindicated due to its potential cardiotoxicity, and doxiciclina should be used with caution in patients taking beta-blockers or other medications that can prolong or alter cardiac conduction, as recommended by the CDC 1
All antimalarials should be stored out of the reach of children as overdose can be fatal, and extreme caution should be used when using quinina to treat individuals who have taken mefloquina as prophylaxis due to similar cardiovascular and neurological toxicity, according to the CDC 1

Travelers should wear clothing that covers most of the body to prevent mosquito bites, apply DEET-containing repellent to exposed skin, and avoid applying DEET-containing repellent to wounds or irritated skin, as recommended by the CDC 1
Clothing treatment with permethrin can be used for additional protection against mosquito-borne diseases, and pyrethrum-containing flying-insect spray can be used in living and sleeping areas, as recommended by the CDC 1
Treated mosquito nets, such as those impregnated with permethrin at 0.2 g/m², are recommended by the World Health Organization (WHO) for sleeping areas to prevent mosquito-borne diseases 2

For standard tourist travel to Egypt, chemoprophylaxis is typically not necessary due to the low risk of malaria and chloroquine-sensitive status, but for certain high-risk travelers or those visiting specific rural areas, chloroquine may be considered, as recommended by the CDC 1
The CDC recommends the following chemoprophylaxis options:

Pregnant women should avoid travel to areas with chloroquine-resistant P. falciparum if possible, according to the CDC, but chloroquine and proguanil have a long history of safe use during pregnancy, and mefloquine can be used in second and third trimesters, as recommended by the American College of Obstetricians and Gynecologists (ACOG) 1, 2
Children ≥15 kg should receive the same chemoprophylaxis options as adults, with adjusted dosing, while children <15 kg should receive chloroquine, as mefloquine is contraindicated in this age group, according to the American Academy of Pediatrics (AAP) 1
Travelers with medical conditions that increase malaria susceptibility, such as asplenia, pregnancy, or immunocompromise, should consult with a travel medicine specialist before traveling to low-risk areas, as advised by the International Society of Travel Medicine (ISTM) 2

Malaria symptoms can develop as early as 8 days after exposure or as late as several months after return, and travelers should seek immediate medical attention if fever develops within 3 months of return, as recommended by the CDC 1
Travelers should continue prophylaxis for the recommended duration after leaving the malarious area (4 weeks for most medications, 7 days for atovaquone-proguanil) and seek medical attention immediately if fever develops within 3 months of return, as recommended by the CDC 2
Travelers should be aware of malaria symptoms, such as fever, chills, headache, and muscle aches, for up to 1 year after return, and seek immediate medical attention if fever develops within 3 months of return, informing healthcare providers of travel history, as recommended by the American Society of Tropical Medicine and Hygiene (ASTMH) 2